AP -- Anadys Pharmaceuticals Inc. said Thursday its experimental hepatitis C drug is meeting key goals in a midstage clinical trial. The company said 56 percent of patients receiving ANA598 in a combination treatment had undetectable levels of the virus after four weeks, based on the interim data. The patients also received pegylated interferon and Ribavirin, which is considered the standard of care for the virus.
